Professor of Medicine, Dermatology, and Translational Science, University Pittsburgh
Oncology
Dr. John M. Kirkwood, MD
|
|
Give Review
Doctor John M. Kirkwood, MD works in the field of Oncology. He went to Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "Pittsburgh Magazine". John M. Kirkwood, MD is a published MD. He has 101 papers published. The most current publication "BRAF Inhibitors and IFN: Plus, Minus, or Indeterminate?"
Publications
- BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?
- Transcriptional repression of IFNβ1 by ATF2 confers Melanoma resistance to therapy.
- Unfolding the mutational landscape of human Melanoma.
- Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype.
- Classification of current antiCancer immunotherapies.
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic Melanoma: a randomized clinical trial.
- Addressing the Knowledge Gap in Clinical Recommendations for Management and Complete Excision of Clinically Atypical Nevi/Dysplastic Nevi: Pigmented Lesion Subcommitte...
- Reply to the letter to the editor of Schilling et al."Differential inï¬uence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efï¬cacy in ...
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interfero...
- State of Melanoma: An Historic Overview of a Field in Transition.
- Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk Melanoma treated with adjuvant interferon alfa.
- Correlation of somatic mutations and clinical outcome in Melanoma patients treated with carboplatin, paclitaxel, and sorafenib.
- PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in Melanoma cells with BRAF mutation.
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines.
- Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Meta...
- Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against Melanoma.
- ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602).
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Pediatric Melanoma: Analysis of an international registry.
- Melanoma Brain Metastases: an Unmet Challenge in the Era of Active Therapy.
- Age as a prognostic factor in patients with localized Melanoma and regional metastases.
- Pathologic and gene expression features of metastatic melanomas to the Brain.
- A Randomized Phase II Trial of Multi-epitope Vaccination withMelanoma Peptides for Cytotoxic T-Cells and Helper T-Cells forPatients with Metastatic Melanoma (E1602).
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma.
- Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice.
- Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma.
- Targeted therapies: BREAKing a path for progress-dabrafenib confirms class effect.
- New therapies in the treatment of Melanoma.
- Comparative clinical benefits of Systemic adjuvant therapy for paradigm solid tumors.
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438).
- CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
- Pitfalls in retrospective analyses of biomarkers: A case study with metastatic Melanoma patients.
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma.
- New challenges in endpoints for drug development in advanced Melanoma.
- Phase II, Open-Label, Randomized Trial of the MEK 1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma.
- Function but not phenotype of Melanoma peptide-specific CD8(+) T cells correlate with survival in a multi-epitope peptide vaccine trial (ECOG 1696).
- Multiplex Serum Biomarker Assessments: Technical and Biostatistical Issues.
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258)-an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors-in Patients with Advanced Melanoma.
- Neoadjuvant therapy for high-risk bulky regional Melanoma.
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin.
- Melanoma response and resistance - taking it to the tumor bank.
- Melanoma Response and Resistance-Taking It to the Tumor Bank.
- Dendritic cells in Cancer immunotherapy: vaccines or autologous transplants?
- Methylation levels of the "Long Interspersed Nucleotide Element-1" repetitive sequences predict survival of Melanoma patients.
- Helper activity of natural killer cells during the dendritic cell-mediated induction of Melanoma-specific cytotoxic T cells.
- Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.
- A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic Melanoma.
- Outcome predictors of Gamma Knife surgery for melanoma Brain metastases. Clinical article.
- Prognostic significance of autoimmunity during treatment of Melanoma with interferon.
- Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
- Adjuvant therapy: Melanoma.
- Systematic review of medical treatment in melanoma: current status and future prospects.
- CTLA-4-blocking immunotherapy with ipilimumab for advanced Melanoma.
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in Melanoma patients.
- Correlation of molecular human leukocyte antigen typing and outcome in high-risk Melanoma patients receiving adjuvant interferon.
- Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide Melanoma vaccines.
- Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
- Multivariate analysis of prognostic factors among 2,313 patients with stage III Melanoma: comparison of nodal micrometastases versus macrometastases.
- Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary Melanoma are prognostic factors for relapse-free survival of patients with thick (t4) p...
- Pharmacodynamic (phase 0) study using etaracizumab in advanced Melanoma.
- Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed Melanoma.
- Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells.
- Final version of 2009 AJCC Melanoma staging and classification.
- Clinical and immunologic basis of interferon therapy in Melanoma.
- Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide Melanoma vaccine: outcome of a multicenter r...
- Melanoma in pediatric, adolescent, and young adult patients.
- A risk variant in an miR-125b binding site in BMPR1B is associated with breast Cancer pathogenesis.
- Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid Tumors.
- Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unre...
- Biomarkers of therapeutic response in Melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
- PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in Melanoma patients.
- Highlights from the perspectives in Melanoma XII conference.
- Predictors of response to interferon therapy.
- Phase I/II trial of tremelimumab in patients with metastatic Melanoma.
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic Melanoma.
- Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic mel...
- Prognostic significance of serum S100B protein in high-risk surgically resected Melanoma patients participating in Intergroup Trial ECOG 1694.
- Effects of high-dose IFNalpha2b on regional lymph node metastases of human Melanoma: modulation of STAT5, FOXP3, and IL-17.
- Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and d...
- A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic Melanoma.
- Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in Melanoma patients.
- STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of Systemic IFNalpha therapy.
- Next generation of immunotherapy for Melanoma.
- Resolving "kinks" of chemotherapy in Melanoma.
- A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with Cancer.
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced Melanoma.
- Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
- Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for Melanoma: expert opinion.
- Safety and efficacy of arsenic trioxide for patients with advanced metastatic Melanoma.
- Expression of ICOS on human Melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
- Meta-analysis of phase II cooperative group trials in metastatic stage IV Melanoma to determine progression-free and overall survival benchmarks for future phase II tr...
- Strong signature of natural selection within an FHIT intron implicated in prostate Cancer risk.
- Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in Melanoma patients.
- Management of metastatic Melanoma.
- A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.
- Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic Melanoma who have experienced progression after biochemotherapy.
- Integrins and Cancer.
- Multiplex analysis of serum cytokines in Melanoma patients treated with interferon-alpha2b.
- Modulation of signal transducers and activators of transcription 1 and 3 signaling in Melanoma by high-dose IFNalpha2b.
- Chemotherapy for metastatic Melanoma: time for a change?
Schools
Yale Univ Sch Of Med
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Pittsburgh Magazine
Education
-
Yale-New Haven Hospital -
Yale University School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1528036449 | |
| NPPES Provider LastName | KIRKWOOD | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 152321309 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 196.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 12.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528036449 |
| Last Name Of The Provider | KIRKWOOD |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Narinder K. Malhotra, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohtesh S. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min E. Sun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Srodes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Georgiadis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dulabh K. Monga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan N. Bress, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salman M. Fazal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna M. Johnsen, MD |